TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Altwegg, Romain ^a   Vincent, Thierry ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT OUTCOME; ALGORITHM; ANTAGONISTS AND INHIBITORS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; PROCEDURES; QUALITY OF LIFE;

ALGORITHMS; BIOLOGICAL PRODUCTS; DRUG MONITORING; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897507346     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/172821     Document Type: Review

References (73)

1. Danese S., Colombel J. F., Peyrin-Biroulet L., Rutgeerts P., Reinisch W., Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Alimentary Pharmacology & Therapeutics 2013 37 9 855 866
2. Peyrin-Biroulet L., Lémann M., Review article: remission rates achievable by current therapies for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2011 33 8 870 879 2-s2.0-79952788410 10.1111/j.1365-2036.2011.04599.x
3. Maser E. A., Villela R., Silverberg M. S., Greenberg G. R., Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clinical Gastroenterology and Hepatology 2006 4 10 1248 1254 2-s2.0-33749432435 10.1016/j.cgh.2006.06.025 (Pubitemid 44512213)
4. Seow C. H., Newman A., Irwin S. P., Steinhart A. H., Silverberg M. S., Greenberg G. R., Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010 59 1 49 54 2-s2.0-73449088039 10.1136/gut.2009.183095
5. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., Rutgeerts P., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. The New England Journal of Medicine 2003 348 7 601 608 2-s2.0-0037434552 10.1056/NEJMoa020888 (Pubitemid 36204954)
6. Afif W., Loftus E. V. Jr., Faubion W. A., Kane S. V., Bruining D. H., Hanson K. A., Sandborn W. J., Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. The American Journal of Gastroenterology 2010 105 5 1133 1139 2-s2.0-77951974444 10.1038/ajg.2010.9
7. Monteleone I., Pallone F., Monteleone G., Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Medicine 2011 9, article 122 2-s2.0-81055150391 10.1186/1741-7015-9-122
8. Mueller C., Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002 105 1 1 8 2-s2.0-0036161995 10.1046/j.1365-2567. 2002.01329.x (Pubitemid 34128034)
9. MacEwan D. J., TNF receptor subtype signalling: differences and cellular consequences. Cellular Signalling 2002 14 6 477 492 2-s2.0-0036121098 10.1016/S0898-6568(01)00262-5 (Pubitemid 34230583)
10. Wajant H., Pfizenmaier K., Scheurich P., Tumor necrosis factor signaling. Cell Death and Differentiation 2003 10 1 45 65 2-s2.0-0037276438 10.1038/sj.cdd.4401189 (Pubitemid 36511832)
11. Aspalter R. M., Eibl M. M., Wolf H. M., Regulation of TCR-mediated T cell activation by TNF-RII. Journal of Leukocyte Biology 2003 74 4 572 582 2-s2.0-0346100668 10.1189/jlb.0303112 (Pubitemid 38040385)
12. Dahlen R., Strid H., Lundgren A., Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scandinavian Journal of Immunology 2013 78 3 275 284 10.1111/sji.12081
13. Chen X., Wu X., Zhou Q., Howard O. M., Netea M. G., Oppenheim J. J., TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. Journal of Immunology 2013 190 3 1076 1084
14. Chen X., Oppenheim J. J., Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Letters 2011 585 23 3611 3618 2-s2.0-80052680230 10.1016/j.febslet.2011.04.025
15. Wang K., Han G., Dou Y., Opposite role of tumor necrosis factor receptors in dextran sulfate sodium-induced colitis in mice. PLoS ONE 2012 7 12 e52924
16. Danese S., Colombel J.-F., Reinisch W., Rutgeerts P. J., Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Alimentary Pharmacology and Therapeutics 2011 33 8 857 869 2-s2.0-79952795096 10.1111/j.1365-2036.2011.04598.x
17. Hanauer S. B., Kornbluth A. A., Messick J., Rubin D. T., Sandborn W. J., Sands B. E., Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflammatory Bowel Diseases 2010 16 1 S1 S11 2-s2.0-78649606965 10.1002/ibd.21529
18. Billiet T., Rutgeerts P., Ferrante M., Van Assche G., Vermeire S., Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2014 14 1 75 101
19. Targan S. R., Hanauer S. B., Van Deventer S. J. H., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease. The New England Journal of Medicine 1997 337 15 1029 35 2-s2.0-0030954732 10.1056/NEJM199710093371502 (Pubitemid 27430520)
20. Dignass A., Van Assche G., Lindsay J. O., Lémann M., Söderholm J., Colombel J. F., Danese S., D'Hoore A., Gassull M., Gomollón F., Hommes D. W., Michetti P., O'Morain C., Öresland T., Windsor A., Stange E. F., Travis S. P. L., The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 2010 4 1 28 62 2-s2.0-75149161836 10.1016/j.crohns.2009.12.002
21. Dignass A., Lindsay J. O., Sturm A., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. Journal of Crohn's and Colitis 2012 6 10 991 1030
22. Hyams J. S., Lerer T., Griffiths A., Pfefferkorn M., Stephens M., Evans J., Otley A., Carvalho R., MacK D., Bousvaros A., Rosh J., Grossman A., Tomer G., Kay M., Crandall W., Oliva-Hemker M., Keljo D., Leleiko N., Markowitz J., Outcome following infliximab therapy in children with ulcerative colitis. The American Journal of Gastroenterology 2010 105 6 1430 1436 2-s2.0-77953232539 10.1038/ajg.2009.759
23. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., Liu G., Travers S., Heuschkel R., Markowitz J., Cohen S., Winter H., Veereman-Wauters G., Ferry G., Baldassano R., Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007 132 3 863 873 2-s2.0-33947397636 10.1053/j.gastro.2006.12.003 (Pubitemid 46454266)
24. Russell R. K., Wilson M. L., Loganathan S., Bourke B., Kiparissi F., Mahdi G., Torrente F., Rodrigues A., Davies I., Thomas A., Akobeng A. K., Fagbemi A., Hyer W., Spray C., Vaish S., Rogers P., McGrogan P., Heuschkel R. B., Ayub N., Fell J. M., Afzal N. A., Green M., Murphy M. S., Rao P., Shah N., Ho G.-T., Naik S., Wilson D. C., A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2011 33 8 946 953 2-s2.0-79952803048 10.1111/j.1365-2036.2011.04603.x
25. Mian S., Baron H., Adalimumab, a novel anti-tumor necrosis factor- α antibody in a child with refractory Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition 2005 41 3 357 359 2-s2.0-24644445063 10.1097/01.mpg.0000169275.86308.b0 (Pubitemid 41285833)
26. Colombel J. F., Sandborn W. J., Reinisch W., Mantzaris G. J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R. H., Broussard D. L., Tang K. L., Van Der Woude C. J., Rutgeerts P., Infliximab, azathioprine, or combination therapy for Crohn's disease. The New England Journal of Medicine 2010 362 15 1383 1395 2-s2.0-77950988234 10.1056/NEJMoa0904492
27. Sands B. E., Blank M. A., Patel K., Van Deventer S. J., Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clinical Gastroenterology and Hepatology 2004 2 10 912 920 2-s2.0-5044235159 10.1016/S1542-3565(04)00414-8 (Pubitemid 39335798)
28. Colombel J.-F., Sandborn W. J., Rutgeerts P., Enns R., Hanauer S. B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J. D., Pollack P. F., Adalimumab for maintenance of clinical response and remission inpatients with Crohn's disease: the CHARM Trial. Gastroenterology 2007 132 1 52 65 2-s2.0-33846242958 10.1053/j.gastro.2006.11.041 (Pubitemid 46108762)
29. Schreiber S., Rutgeerts P., Fedorak R. N., Khaliq-Kareemi M., Kamm M. A., Boivin M., Bernstein C. N., Staun M., Thomsen O., Innes A., A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005 129 807 818 2-s2.0-27744607852 (Pubitemid 41242673)
30. Sandborn W. J., Feagan B. G., Marano C., Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014 146 1 96.e1 109.e1
31. Sandborn W. J., Feagan B. G., Marano C., Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014 146 1 85 95
32. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P., Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009 58 4 492 500 2-s2.0-63849101007 10.1136/gut.2008.155812
33. Yanai H., Hanauer S. B., Assessing response and loss of response to biological therapies in IBD. The American Journal of Gastroenterology 2011 106 4 685 698 2-s2.0-79953788656 10.1038/ajg.2011.103
34. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., Ternant D., Watier H., Paintaud G., Rutgeerts P., Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008 134 7 1861 1868 2-s2.0-44649090092 10.1053/j.gastro.2008.03.004 (Pubitemid 351790744)
35. Billioud V., Sandborn W. J., Peyrin-Biroulet L., Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. The American Journal of Gastroenterology 2011 106 4 674 684 2-s2.0-79953786419 10.1038/ajg.2011.60
36. Sandborn W. J., Colombel J.-F., Schreiber S., Plevy S. E., Pollack P. F., Robinson A. M., Chao J., Mulani P., Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflammatory Bowel Diseases 2011 17 1 141 151 2-s2.0-78650159235 10.1002/ibd.21328
37. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W. J., Colombel J.-F., Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008 6 6 644 653 2-s2.0-44649187924 10.1016/j.cgh.2008.03.014 (Pubitemid 351783447)
38. Fasanmade A. A., Adedokun O. J., Blank M., Zhou H., Davis H. M., Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 Phase III clinical trials. Clinical Therapeutics 2011 33 7 946 964 2-s2.0-79960283949 10.1016/j.clinthera. 2011.06.002
39. Fasanmade A. A., Adedokun O. J., Ford J., Hernandez D., Johanns J., Hu C., Davis H. M., Zhou H., Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. European Journal of Clinical Pharmacology 2009 65 12 1211 1228 2-s2.0-71249099165 10.1007/s00228-009-0718-4
40. Ordás I., Mould D. R., Feagan B. G., Sandborn W. J., Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clinical Pharmacology and Therapeutics 2012 91 4 635 646 2-s2.0-84858793037 10.1038/clpt.2011.328
41. Nanda K. S., Cheifetz A. S., Moss A. C., Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. The American Journal of Gastroenterology 2013 108 1 40 47
42. Xu Z., Seitz K., Fasanmade A., Ford J., Williamson P., Xu W., Davis H. M., Zhou H., Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. Journal of Clinical Pharmacology 2008 48 6 681 695 2-s2.0-44049096982 10.1177/0091270008316886 (Pubitemid 351713154)
43. Moss A. C., Brinks V., Carpenter J. F., Review article: immunogenicity of anti-TNF biologics in IBD-the role of patient, product and prescriber factors. Alimentary Pharmacology & Therapeutics 2013 38 10 1188 1197
44. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007 56 9 1226 1231 2-s2.0-34548130215 10.1136/gut.2006.099978 (Pubitemid 47300423)
45. Bortlik M., Duricova D., Malickova K., Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. Journal of Crohn's and Colitis 2012 7 9 736 743
46. Steenholdt C., Bendtzen K., Brynskov J., Thomsen O. Ø., Ainsworth M. A., Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scandinavian Journal of Gastroenterology 2011 46 3 310 318 2-s2.0-79751477764 10.3109/00365521.2010. 536254
47. Hibi T., Sakuraba A., Watanabe M., Motoya S., Ito H., Motegi K., Kinouchi Y., Takazoe M., Suzuki Y., Matsumoto T., Kawakami K., Matsumoto T., Hirata I., Tanaka S., Ashida T., Matsui T., Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflammatory Bowel Diseases 2012 18 8 1480 1487 2-s2.0-80053595588 10.1002/ibd.21886
48. Adedokun O. J., Xu Z., Padgett L., Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflammatory Bowel Diseases 2013 19 13 2753 2762
49. Paul S., Del Tedesco E., Marotte H., Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflammatory Bowel Diseases 2013 19 12 2568 2576 10.1097/MIB. 0b013e3182a77b41
50. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., Coscas D., Bar-Meir S., Goldstein I., Chowers Y., The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011 60 1 41 48 2-s2.0-78651237721 10.1136/gut.2009.201533
51. Ainsworth M. A., Bendtzen K., Brynskov J., Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. The American Journal of Gastroenterology 2008 103 4 944 948 2-s2.0-41849135759 10.1111/j.1572-0241.2007.01638.x (Pubitemid 351501078)
52. Imaeda H., Bamba S., Takahashi K., Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. Journal of Gastroenterology. In press
53. Pariente B., De Chambrun G. P., Krysiek R., Desroches M., Louis G., De Cassan C., Baudry C., Gornet J.-M., Desreumaux P., Emilie D., Colombel J.-F., Allez M., Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2012 18 7 1199 1206 2-s2.0-80052102794 10.1002/ibd.21839
54. Cassinotti A., Travis S., Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflammatory Bowel Diseases 2009 15 8 1264 1275 2-s2.0-70349512283 10.1002/ibd.20899
55. Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P., Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology 2004 2 7 542 553 2-s2.0-3042579454 10.1016/S1542-3565(04)00238-1 (Pubitemid 38834038)
56. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., Claes K., Coopman T., Van Schuerbeek N., Van Assche G., Vermeire S., Rutgeerts P., Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009 137 5 1628 1640 2-s2.0-70350130547 10.1053/j.gastro.2009.07.062
57. Chiu Y. L., Rubin D. T., Vermeire S., Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflammatory Bowel Diseases 2013 19 6 1112 1122
58. Roblin X., Marotte H., Rinaudo M., Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology 2014 12 1 80.e2 84.e2
59. Bartelds G. M., Wijbrandts C. A., Nurmohamed M. T., Stapel S., Lems W. F., Aarden L., Dijkmans B. A. C., Tak P. P., Wolbink G. J., Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 7 921 926 2-s2.0-34347267600 10.1136/ard.2006.065615 (Pubitemid 46999794)
60. West R. L., Zelinkova Z., Wolbink G. J., Kuipers E. J., Stokkers P. C. F., Van Der Woude C. J., Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics 2008 28 9 1122 1126 2-s2.0-53549083244 10.1111/j.1365-2036.2008. 03828.x
61. Imaeda H., Takahashi K., Fujimoto T., Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. Journal of Gastroenterology 2014 49 1 100 109 10.1007/s00535-013-0803-4
62. Bartelds G. M., Krieckaert C. L. M., Nurmohamed M. T., Van Schouwenburg P. A., Lems W. F., Twisk J. W. R., Dijkmans B. A. C., Aarden L., Wolbink G. J., Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up. Journal of the American Medical Association 2011 305 14 1460 1468 2-s2.0-79953906254 10.1001/jama.2011.406
63. Vermeire S., Gils A., Value of drug level testing and antibody assays in optimising biological therapy. Frontline Gastroenterology 2013 4 1 41 43
64. Cleynen I., Vermeire S., Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nature Reviews Gastroenterology & Hepatology 2012 9 9 496 503
65. Ben-Horin S., Waterman M., Kopylov U., Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2013 11 4 444 447
66. Steenholdt C., Al-khalaf M., Brynskov J., Bendtzen K., Thomsen O., Ainsworth M. A., Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2012 18 12 2209 2217 2-s2.0-84856937226 10.1002/ibd.22910
67. Vande Casteele N., Gils A., Singh S., Antibody response to infliximab and its impact on pharmacokinetics can be transient. The American Journal of Gastroenterology 2013 108 6 962 971 10.1038/ajg.2013.12
68. Ungar B., Chowers Y., Yavzori M., The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2013 10.1136/gutjnl-2013-305259
69. Velayos F. S., Kahn J. G., Sandborn W. J., Feagan B. G., A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's Disease who lose responsiveness to infliximab. Clinical Gastroenterology and Hepatology 2013 11 6 654 666
70. Steenholdt C., Brynskov J., Thomsen O. O., Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2013 10.1136/gutjnl-2013-305279
71. Vande Casteele N., Buurman D. J., Sturkenboom M. G., Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Alimentary Pharmacology & Therapeutics 2012 36 8 765 771
72. Buurman D. J., Vande Casteele N., Sturkenboom M. G., Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays, authors' reply. Alimentary Pharmacology & Therapeutics 2013 37 2 282
73. Parussini E., Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays. Alimentary Pharmacology & Therapeutics 2013 37 2 281